Posts

Posted on

CLOV 4-DAY DEADLINE ALERT: HAGENS BERMAN, National Trial Attorneys, Alerts Clover Health Investments (CLOV) Investors to April 6th Deadline in Securities Class Action, Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) — Hagens Berman encourages Clover Health Investments, Corp. (NASDAQ: CLOV) investors to submit their losses now.   A securities fraud class action has been filed and certain investors may have valuable claims.

Class Period: Oct. 6, 2020 – Feb. 4, 2021
Lead Plaintiff Deadline: Apr. 6, 2021
Visit:www.hbsslaw.com/cases/CLOV
Contact An Attorney Now:[email protected]
                                              844-916-0895

Clover Health Investments, Corp. (CLOV) Securities Class Action:

The Complaint alleges that, throughout the Class Period, Defendants misrepresented and concealed that: (1) Clover’s Clover Assistant platform was under investigation by the Department of Justice for at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals; (2) the DOJ’s investigation presented an existential risk to Clover because it derives most of its revenues from Medicare; and (3) Clover’s sales were driven by a major undisclosed related party deal and misleading marketing targeting the elderly, not its purported “best-in-class” technology.

Investors allegedly began to learn the truth on Feb. 4, 2021 when Hindenburg Research released a scathing report about the company, alleging Clover’s sales are the product of misleading marketing activities targeting the elderly and a major undisclosed related party deal.

Hindenburg claimed that Clover concealed that the DOJ is actively investigating the company for illegal kickbacks and deceptive marketing practices. Hindenburg alleged that the company uses a subsidiary, Seek Insurance Services, to misleadingly steer seniors toward acquiring Clover plans. Citing accounts from former employees, Hindenburg further stated “that much of Clover’s sales are fueled by a major undisclosed relationship between Clover and [B&H Assurance,] an outside brokerage firm controlled by Clover’s Head of Sales (Hiram Bermudez).”

The next day, Clover admitted it was fully aware of the DOJ inquiry and Bermudez’s ownership in B&H Assurance. The company also revealed that it received a letter from the SEC following Hindenburg’s report.

On this news, the price of Clover shares sharply declined.

“We’re focused on investor losses and whether Clover may have misled investors about the legality of its business practices and related financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Clover shares, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Clover should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30% of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895



Posted on

Kessler Topaz Meltzer & Check, LLP: Final Deadline Reminder for Clover Health Investments, Corp. Investors – CLOV

RADNOR, Pa., April 02, 2021 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee against Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover”) on behalf of those who purchased or acquired Clover publicly traded securities between October 6, 2020 and February 4, 2021, inclusive (the “Class Period”), and/or purchased or acquired Clover securities pursuant or traceable to Clover’s registration statement and prospectus issued in connection with the December 2020 Merger.



FINAL REMINDER



:


Clover


investors may,



no later than April 6, 2021



, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at

[email protected]; orclick https://www.ktmc.com/clover-health-investments-corp-securities-class-action?utm_source=PR&utm_medium=link&utm_campaign=clover

According to the complaint, Clover provides health insurance services. Clover was taken public through a reverse merger with IPOC, a Special Purpose Acquisition Company (the “Business Combination”). Prior to the Business Combination, IPOC traded on the New York Stock Exchange. The Class Period commences on October 6, 2020, when Clover issued a press release announcing its intention to become a public company through a merger with IPOC. On October 20, 2020, Clover filed its registration statement and preliminary proxy statement/prospectus on a Form S-4 with the SEC (the “Registration Statement”). The Registration Statement was amended on December 9, 2020 and December 10, 2020, and was declared effective on December 11, 2020. The Registration Statement touted Clover’s growth as strong and organic.

On February 4, 2021, before market hours, Hindenburg Research published a research report that revealed that Clover’s flagship platform, Clover Assistant, was the subject of a U.S. Department of Justice (“DOJ”) investigation for a variety of issues, including illegal kickbacks, marketing practices, and undisclosed related-party transactions. Hindenburg discovered that Clover’s sales growth was not driven by technology, but by deceptive sales practices. Following this news, Clover common stock (CLOV) fell $1.72 per share, or 12.3%, to close at $12.23 per share on February 4, 2021, and Clover warrants (CLOVW) fell $0.18 per warrant, or 5%, to close at $3.39 per warrant on February 4, 2021.

On February 5, 2021, before the market opened, Clover filed a Form 8-K disclosing that the SEC was conducting an “investigation and requesting document and data preservation for the period from January 1, 2020, to the present, relating to certain matters that are referenced in the [Hindenburg Research report].” Following this news, Clover common stock (CLOV) fell $0.53 per share, or 4.3% during intraday trading on February 5, 2021, and Clover warrants (CLOVW) fell $0.28 per warrant, or 8.2% during intraday trading on February 5, 2021.

The complaint alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Clover was under active investigation by the DOJ for at least 12 issues ranging from illegal kickbacks, to marketing practices, to undisclosed related-party deals; (2) the DOJ’s investigation presented an existential risk to Clover, since it derives most of its revenues from Medicare; (3) Clover’s sales were driven by a major undisclosed related-party deal and misleading marketing targeting the elderly, not its purported “best-in-class” technology; (4) a significant portion of Clover sales were from an undisclosed relationship between Clover and a brokerage firm controlled by Clover’s Head of Sales; and (5) as a result, the defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis.

Clover investors may, no later than April 6, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP, or other counsel, or may choose to do nothing and remain an absent class member.  A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
[email protected]



Posted on

SmileDirectClub Announces Appointment of Ted Ward to Board of Directors

AdAge Power Player Brings to Company’s Board More Than Three Decades of Marketing Expertise as GEICO CMO

NASHVILLE, Tenn., April 02, 2021 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced the appointment of Ted Ward as a director on its Board.

Ward is a respected marketing titan with over three decades of experience, most recently at the helm of the marketing team at insurance giant GEICO, where he led the creation of the company’s award-winning disruptive marketing campaigns and solidified the brand as an industry innovator in the minds of consumers.

“Ted brings invaluable marketing expertise in guiding a challenger brand to unseat the incumbent market leader, and we look forward to having Ted help SmileDirectClub’s award-winning marketing team go even further and faster,” said David Katzman, Chief Executive Officer and Chairman of SmileDirectClub. “His experience compliments our Board and will prove beneficial as we continue to educate consumers on the clinically safe and effective treatment SmileDirectClub offers without the 3x markup.”

As Ted joins the SmileDirectClub Board, Rick Schnall has resigned his position as a director. The executive management team and the Board of Directors of SmileDirectClub thank Rick for his commitment and service to SmileDirectClub and wish him the best in his future endeavors.

About SmileDirectClub

SmileDirectClub, Inc. (Nasdaq: SDC) (“SmileDirectClub”) is an oral care company and creator of the first medtech platform for teeth straightening, now also offered directly via dentist and orthodontist offices. Through its proprietary technology and vertically integrated model, SmileDirectClub is revolutionizing the oral care industry, offering consumers the ability to get clinically safe and effective treatment but without the 3x markup associated with traditional orthodontics. SmileDirectClub’s mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone, from clear aligner therapy to premium oral care products. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Australia, New Zealand, United Kingdom, Ireland, Germany, Austria, Spain, Netherlands, Hong Kong, Singapore and Mexico. For more information, please visit SmileDirectClub.com.

Contact: SmileDirectClub Media Relations: [email protected]



Posted on

Small Business Hiring Growth Continues in March

Small Business Hiring Growth Continues in March

The CBIZ Small Business Employment Index sees positive hiring trends for the second consecutive month, building on February’s bounce from early-year declines

CLEVELAND–(BUSINESS WIRE)–
The CBIZ Small Business Employment Index (“SBEI”) reported a seasonally adjusted increase of 0.86% for March. The reading closes the first quarter of 2021 on a positive note and builds on February’s hiring growth. The CBIZ SBEI tracks payroll and hiring trends for over 3,500 companies that have 300 or fewer employees, providing broad insight into small business trends.

“The small business landscape has been greatly impacted by the pandemic over the last year, and recovery has not been linear,” said Philip Noftsinger, Executive Vice President, CBIZ, Inc. “The CBIZ SBEI’s continued growth in March is a promising sign.”

Hiring growth was also evident in the ADP and Moody’s employment report, which revealed an uptick of 517,000 private-sector jobs on a month-over-month, seasonally adjusted basis. The boost for small business jobs was 174,000. The ADP and Moody’s report counts small businesses as companies with 49 or fewer employees, while the CBIZ SBEI uses data from companies with 300 employees or fewer.

The CBIZ SBEI showed positive trends in the regional data for March, with widespread hiring increases. The Northeast (1.61%) and West (1.27%) saw the most significant rises in hiring. These regions were followed by more modest gains in the Southeast (0.82%) and Central (0.61%) U.S.

The industry data from the CBIZ SBEI also painted a positive picture. While hiring increased in Construction and Financial Services, boosts in Arts and Entertainment as well as Accommodation and Food Services were particularly noteworthy, due to the impact of pandemic-related restrictions on these industries. Meanwhile, hiring declined in only two industries, Mining along with Technology and Life Sciences.

“With the impact of the pandemic in mind, we’ve been paying close attention to the Arts and Entertainment industry and the Accommodation and Food Services industry, which each posted almost double-digit hiring growth in March,” Noftsinger added. “Arts and Entertainment in particular trended negatively in February, underscoring the significance of improvement in March.”

To view an infographic with data from the employment index, visit the CBIZ website.

Additional takeaways from the March SBEI include:

March’s snapshot: 26.3% of companies in the index added to their headcounts, 56.2% maintained employment levels and 17.5% decreased their headcounts.

Industries at a glance: The CBIZ SBEI reported increased hiring inArts and Entertainment, Accommodation and Food Services, Construction, and Financial Services. Hiring decreased in Mining as well as Technology and Life Sciences.

Geographical hiring: On a regional scale, hiring increased unanimously across the Northeast (1.61%), West (1.27%), Southeast (0.82%) and Central (0.61%) U.S.

What’s next? In terms of economic recovery, regional and industry data will continue to be telling for the small business sector moving into the second quarter of 2021.

The CBIZ SBEI March reading comes on the heels of the Q1 2021 release of the CBIZ Main Street Index, which surveyed over 2,480 businesses throughout the U.S. on the continued impact of the COVID-19 pandemic.* The Q1 2021 CBIZ Main Street Index reported that while 44% of businesses surveyed experienced a significant or severe impact from the pandemic, almost three-quarters indicated positive or very positive levels of business confidence. Please see the CBIZ Main Street Index webpage for an interactive infographic with additional data.

*Note: Not all of those surveyed in the CBIZ Main Street Index are clients of CBIZ.

Editor’s note:

(1) The SBEI illustration is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License. Based on our work at https://www.cbiz.com.

Follow CBIZ on Twitter at @CBZ or on Facebook.

About CBIZ

CBIZ, Inc. is a leading provider of financial, insurance and advisory services to businesses throughout the United States. Financial services include accounting, tax, government health care consulting, transaction advisory, risk advisory, and valuation services. Insurance services include employee benefits consulting, retirement plan consulting, property and casualty insurance, payroll, and human capital consulting. With more than 100 Company offices in 31 states, CBIZ is one of the largest accounting and insurance brokerage providers in the U.S. For more information, visit www.cbiz.com.

Media

Sandy McKenzie

Gregory FCA for CBIZ

[email protected]

610-228-2147

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Insurance Human Resources Finance Consulting Banking Accounting Professional Services Small Business Other Professional Services

MEDIA:

Logo
Logo
Posted on

Churchill Capital Corp VII Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing April 5, 2021

PR Newswire

NEW YORK, April 2, 2021 /PRNewswire/ — Churchill Capital Corp VII (the “Company” or “Churchill“) announced that commencing April 5, 2021, holders of the units sold in the Company’s initial public offering of 138,000,000 units may elect to separately trade the shares of Class A common stock and warrants included in the units. Shares of Class A common stock and warrants that are separated will trade on the New York Stock Exchange under the symbols “CVII” and “CVII WS,” respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol “CVII.U”. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Churchill Capital Corp VII

Churchill Capital Corp VII was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of Churchill Capital Corp VII may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC“). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:

Churchill Capital Corp VII
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/churchill-capital-corp-vii-announces-the-separate-trading-of-its-class-a-common-stock-and-warrants-commencing-april-5-2021-301261361.html

SOURCE Churchill Capital Corp VII

Posted on

Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

PR Newswire

SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company’s Board of Directors as an independent non-executive director, effective on March 31, 2021.

Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America’s best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biopharmaceutical industry. Dr. Sidransky is currently the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology; and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the Johns Hopkins University School of Medicine. Dr. Sidransky is also serving as a member on the Scientific Advisory Boards of numerous professional organizations and institutions, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) of the U.S. Having authored over 550 peer-reviewed publications, contributed 45 cancer reviews and chapters, and invented 28 biotechnology patents, Dr. Sidransky is one of the world’s most highly cited researchers in clinical and medical journals.

Dr. Sidransky has accumulated immense industry experience and exceptional expertise, not only in scientific research, but also in business operations, corporate governance and investment strategies. Dr. Sidransky is a founder of a number of biotechnology companies such as Champions Oncology (Nasdaq; CSBR). Previously, Dr. Sidransky was Vice Chairman of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care, until its acquisition by Eli Lilly. Dr. Sidransky is also a Co-Founder and Managing Partner of the Israel Biotech Fund. Furthermore, Dr. Sidransky is a highly-experienced board member, after having served as a director on the boards of Galmed Pharmaceuticals (Nasdaq: GLMD), Orgenesis (Nasdaq: ORGS), Advaxis (Nasdaq: ADXS), and Ayala (Nasdaq: AYLA).

“It is our great pleasure to welcome Dr. Sidransky join us as an independent non-executive director. Dr. Sidransky is a true expert in science as well as in business operations, corporate governance, and investment management, and has made tremendous contributions to the biopharmaceutical industry,” said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. “Ascentage Pharma is currently advancing the global clinical development of its assets targeting a range of tumor types, and is gearing up for its first product launch. We are confident that the addition of Dr. Sidransky to our board will help sharpen our strategic focus and better position the company to capture future growth opportunities.”

“I am excited to join Ascentage Pharma’s board as an independent non-executive director, and to have the opportunity to work with the company’s leadership team and board members,” commented Dr. Sidransky. “Ascentage Pharma is an emerging global leader in biopharmaceutical innovation. I look forward to supporting the company to realize its founding mission of ‘addressing unmet clinical needs in China and around the world’.”

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and a New Drug Application (NDA) for the drug candidate has been submitted and subsequently granted Priority Review by the Center for Drug Evaluation (CDE) in China. To date, Ascentage Pharma has obtained a total of 11 ODDs from the US FDA for four of the company’s investigational drug candidates.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ascentage-pharma-appoints-renowned-oncologist-dr-david-sidransky-md-to-its-board-as-an-independent-non-executive-director-301261367.html

SOURCE Ascentage Pharma

Posted on

Yalla Group Limited Files 2020 Annual Report on Forms 20-F

PR Newswire

DUBAI, UAE, April 2, 2021 /PRNewswire/ — Yalla Group Limited (“Yalla” or the “Company”) (NYSE: YALA), the leading voice-centric social networking and entertainment platform in the Middle East and North Africa (MENA), today announced that it has filed its annual report on Form 20-F that includes its audited financial statements for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission (the “SEC”) on April 2, 2021, U. S. Eastern Time.

The annual report can be accessed on Yalla’s investor relations website at http://ir.yallatech.ae/ and on the SEC’s website at www.sec.gov. The Company will also provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders and American Depositary Share holders upon request.

About Yalla Group Limited

Yalla Group Limited is the leading voice-centric social networking and entertainment platform in the Middle East and Northern Africa (MENA). The Company’s flagship mobile application, Yalla, is specifically tailored for the people and local cultures of the region and primarily features Yalla rooms, a mirrored online version of the majlis or cafés where people spend their leisure time in casual chats. Voice chats are more suitable to the cultural norms in MENA compared to video chats. The Company strives to maintain users’ equal status on its platform, thereby encouraging all users to freely communicate and interact with each other. The Company also operates Yalla Ludo, a mobile application featuring online versions of board games that are highly popular in MENA, such as Ludo and Domino. In-game real-time chats and Ludo chat room functions are popular social networking features among users. Through close attention to detail and localized appeal that deeply resonates with users, Yalla’s mobile applications deliver a seamless user experience that fosters a loyal sense of belonging, creating a highly devoted and engaged user community.

For more information, please visit: http://ir.yallatech.ae/

For investor and media inquiries, please contact:

Yalla Group Limited
Investor Relations
Kerry Gao – IR Director
Tel: +86-571-8980-7962
Email: [email protected]

The Piacente Group, Inc.
Yang Song
Tel: +86-10-6508-0677
Email: [email protected]

In the United States:

The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/yalla-group-limited-files-2020-annual-report-on-forms-20-f-301261358.html

SOURCE Yalla Group Limited

Posted on

MINISO Mexico Launches Limited Edition Xico Crossover Collection

– This is the first locally initiated IP partnership granted by MINISO headquarters

PR Newswire


GUANGZHOU, China
, April 2, 2021/PRNewswire/ — Spanning over 80 countries with more than 4,514 stores in seven years, MINISO, a lifestyle product retailer, has taken another key step in going global. In Mexico, the brand has released a special limited-edition crossover collection with Xico, an ancient character inspired by the ancestral breed of Xoloitzcuintle dogs that represents Mexico around the world. The partnership, for the first time, has been granted by MINISO headquarters to a regional market for developing its local IP for local markets, which marks the company’s increasing focus on localization in the process of globalization.

Inspired by Mexica Culture, Xico is an IP created by the celebrated Mexican designer Cristina Pineda. “I am very proud to be part of a company that helps ideas come to life and encourages projects like this,” said MINISO Mexico Marketing Manager Mirna Oropeza. “Collaborating with an iconic Mexican designer was a fantastic experience, and it was heart-warming to do something specific for our country together with my fellow colleagues in MINISO headquarters. We will continue working together to come up with fun and meaningful collection ideas, for the Mexican market and others.”

The whole journey of collaboration took 18 months, from the beginning of discussions to the collection’s completion. During this time, the pandemic temporarily delayed the project, while a film on Xico was released on Netflix in 2020, which drew more attention to this IP. After the partnership was inked, the MINISO Mexico team identified the most popular products in the local market, and collaborated with the designer to select the designs from the Xico series, which represents Mexican culture and legends. The Roots and Fighter series were finally selected because they embody happiness and magic in Mexican traditional culture, and hold even greater meaning given the difficult times currently faced by people everywhere. As such, “find your way” is one of the messages that Xico delivers.

There are currently 18 SKUs in the MINISO x Xico collection, which went on sale earlier this month and has been received eagerly by fans. The collection is currently available in Mexico, Colombia, and Peru. If customers in other regions would like to have the Xico collection for sale in their market, MINISO Mexico is receptive to expanding their sales coverage to spread a deeper understanding and appreciation of Mexican culture.

MINISO has collaborated with different brands for crossover collections since its inception, among which the co-branded products of Marvel, Sanrio, We Bare Bears, Adventure Time, Sesame Street, Mickey Mouse and more are loved by fans and consumers worldwide. Looking forward, with respect to local cultures of different areas, MINISO will continue to bring more products of happiness and within easy reach to consumers around the world.

For further information, please visit:

https://www.instagram.com/minisomexico/ 
www.miniso.com 

About MINISO

MINISO (NYSE: MNSO) is a lifestyle product retailer, offering high quality household goods, cosmetics, food, and toys at affordable prices. Since its first store opened in Guangzhou in 2013, MINISO has opened more than 4,514 stores in over 80 countries and regions. With a focus on sleek design and fun trends, its mission is to enable everyone to enjoy life’s little surprises.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/miniso-mexico-launches-limited-edition-xico-crossover-collection-301260274.html

SOURCE Miniso Group

Posted on

Churchill Capital Corp VI Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing April 5, 2021

PR Newswire

NEW YORK, April 2, 2021 /PRNewswire/ — Churchill Capital Corp VI (the “Company” or “Churchill“) announced that commencing April 5, 2021, holders of the units sold in the Company’s initial public offering of 55,200,000 units may elect to separately trade the Class A common stock and warrants included in the units. Class A common stock and warrants that are separated will trade on the New York Stock Exchange under the symbols “CCVI” and “CCVI WS,” respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol “CCVI.U”. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Churchill Capital Corp VI

Churchill Capital Corp VI was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of Churchill Capital Corp VI may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC“). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:

Churchill Capital Corp VI
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/churchill-capital-corp-vi-announces-the-separate-trading-of-its-class-a-common-stock-and-warrants-commencing-april-5-2021-301261360.html

SOURCE Churchill Capital Corp VI

Posted on

Pintec Technology Holdings Limited to Hold 2021 Extraordinary General Meeting on May 7, 2021

PR Newswire

BEIJING, April 2, 2021 /PRNewswire/ — Pintec Technology Holdings Limited (Nasdaq: PT) (“PINTEC” or the “Company”), a leading independent technology platform enabling financial services in China, today announced that it has called an extraordinary general meeting (the “EGM”) of shareholders to be held at Floor 9, Room Jupiter, Heng An Building, No. 17, East 3rd Ring Road, Chaoyang, Beijing on May 7, 2021 at 10:00a.m.Local time to consider and vote on the following two proposals (the “Proposals”) as further detailed in the notice of the EGM (the “Notice”):

  1. THAT the authorized share capital of the Company shall be changed to US$250,000, divided into 2,000,000,000 shares of a par value of US$0.000125 each, comprising of (i) 750,000,000 Class A Ordinary Shares of a par value of US$0.000125 each, (ii) 250,000,000 Class B Ordinary shares of a par value of US$0.000125 each, and (iii) 1,000,000,000 shares of no specific class of a par value of US$0.000125 each, by the re-designation of 1,000,000,000 authorized but unissued Class A Ordinary Shares as shares of no specific class (the “Re-designation of Share Capital”);

  2. THAT the Company’s Fourth or Current Amended and Restated Memorandum of Association and Articles of Association be amended and restated by their deletion in their entirety and by the substitution in their place of the Fifth Amended and Restated Memorandum of Association and Articles of Association in the form as attached as Exhibit A to the Notice.

The detailed Proposals and additional information regarding the EGM can be found in the Notice and the form of proxy for the EGM. The Notice and form of proxy for the EGM are available on the Company’s website at ir.pintec.com, and will also be furnished to the Securities and Exchange Commission on Form 6-K on or about April 2, 2021. In addition, the Company’s proxy materials (including the final proxy statement) will be mailed to shareholders and ADS holders.

The Board of Directors of the Company recommends that the Company’s shareholders and ADS holders vote FOR the Proposals.

The Board of Directors of the Company has fixed the close of business on April 7, 2021 as the record date (the “Record Date”) for determining the shareholders entitled to receive the Notice or any adjournment or postponement thereof. Holders of record of ordinary shares of the Company at the close of business on the Record Date are entitled to notice of, to attend and vote at, the EGM or any adjournment or postponement thereof. Holders of the Company’s American depositary shares (“ADSs”) who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company’s ADS program, The Bank of New York Mellon.

About PINTEC

PINTEC is a leading independent technology platform enabling financial services in China. By connecting business and financial partners on its open platform, PINTEC enables them to provide financial services to end users efficiently and effectively. The Company offers its partners a full suite of customized solutions, ranging from digital retail lending, digital business lending, robotic process automation, to wealth management and insurance products. Leveraging its scalable and reliable technology infrastructure, PINTEC serves a wide range of industry verticals covering online travel, e-commerce, telecommunications, online education, SaaS platforms, financial technology, internet search, and online classifieds and listings, as well as various types of financial partners including banks, brokers, insurance companies, investment funds and trusts, consumer finance companies and other similar institutions. For more information, please visit ir.pintec.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “is expected to,” “anticipates,” “aim,” “future,” “intends,” “plans,” “believes,” “are likely to,” “estimates,” “may,” “should” and similar expressions, and include, without limitation, quotations from management and PINTEC’s strategic and operational plans. PINTEC may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but not limited to, the Company’s limited operating history, regulatory uncertainties relating to online consumer finance in China, the Company’s reliance on Jimu Group for a significant portion of its funding and the need to further diversify its financial partners, the Company’s reliance on a limited number of business partners, the impact of current or future PRC laws or regulations on wealth management financial products, publicity regarding the consumer finance industry and the evolving regulatory environment governing this industry in China, and the Company’s ability to meet the standards necessary to maintain the listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Cision View original content:http://www.prnewswire.com/news-releases/pintec-technology-holdings-limited-to-hold-2021-extraordinary-general-meeting-on-may-7-2021-301261267.html

SOURCE Pintec Technology Holdings Limited